Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Sarcoma × Ferrosoferric Oxide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 4 Brain Neoplasms 4 Esophageal Neoplasms 3 Urinary Bladder Neoplasms 2 Prostatic Neoplasms 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Childhood Brain Neoplasm 2 Triple Negative Breast Neoplasms 1 Thyroid Cancer, Papillary 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rectal Neoplasms 1 Pancreatic carcinoma, familial 1 Pancreatic Neoplasms 1 Pancreatic Intraductal Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Osteonecrosis 1 Osteomyelitis 1 Neurodegenerative Diseases 1 Neoplasms 1 Malignant Solid Neoplasm 1 Lung Carcinoma Metastatic in the Brain 1 Kidney Neoplasms 1 Ischemic Stroke 1 Hypoxia 1

Interventions

Doxorubicin 122 Ifosfamide 71 Radiotherapy 65 Cyclophosphamide 62 Gemcitabine 54 Filgrastim 47 Docetaxel 35 pazopanib 34 pembrolizumab 33 Etoposide 33 Vincristine 31 Trabectedin 31 Cisplatin 29 Nivolumab 27 Irinotecan 21 Magnetic Resonance Spectroscopy 20 Carboplatin 20 Ipilimumab 19 Temozolomide 17 Radiation 17 Bevacizumab 17 Mesna 16 Melphalan 16 Granulocyte Colony-Stimulating Factor 16 Sirolimus 15 Dactinomycin 15 Biopsy 15 eribulin 14 Topotecan 14 Surgical Procedures, Operative 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01663090 2020-10-19

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Dana-Farber Cancer Institute

Phase NA Withdrawn

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡